Company / Net Income
Arrowhead Pharmaceuticals Net Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
-$1.6M
FY2025
5-year range
-$599.5M / -$1.6M
FY2021-FY2025
Trend
+99.7%
vs FY2024
Sector context
#62 of 216
Health Care
What the data says
At -$2M, Arrowhead Pharmaceuticals's net income ranks #62 of 216 in the Health Care sector. Net Income returned to growth in FY2025 after 2 years of decline, reaching -$2M.
Based on SEC 10-K filings.
-$2M in FY2025.
Improved from -$141M to -$2M over the past 2 years.
Health Care sector context is included.
Net Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#62 of 216 in Health CareTop 29% of 216This company -$1.6M Sector average $454.3M
▼
-100.4% below sector average
Key checks
Key Insights
- In FY2025, net income increased 99.7% year-over-year.
- Ranks #62 out of 216 companies in the Health Care sector.
- Lowest net income in the period was in FY2024.
Company context
Key Data Points
- Altman Z-Score 0.43 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$1.6M | +99.7% |
| FY2024 | -$599.5M | -325.6% |
| FY2023 | -$140.8M | -66.6% |
| FY2022 | -$84.6M | +40.0% |
| FY2021 | -$140.8M | -66.6% |
| FY2020 | -$84.6M | -145.9% |
| FY2019 | -$34.4M | +57.9% |
| FY2018 | -$81.7M | +11.1% |
| FY2017 | -$91.9M | -341.7% |
| FY2016 | -$20.8M | +33.2% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026